Identifying Patients

A path to asthma control for different
patient types

Explore how DUPIXENT may help control symptoms in different
types of patients

Up to 84% of Adult Asthma Patients Present With Type 2 Inflammation1,2

Your appropriate patients with Type 2 inflammation, which can be both systemic and local, may benefit from DUPIXENT today3-5

EOS 155 cells/µL

IgE 380 IU/mL


  • 2 severe exacerbations in the past year
  • Compromised lung function: 70% FEV1 % predicted
  • Diagnosed with asthma as a child
  • Positive skin test to a perennial aeroallergen
  • Triple therapy: ICS/LABA + LTRA

test

EOS 320 cells/µL

IgE 430 IU/mL

FeNO 40 ppb

 

  • 2 severe exacerbations in the past year
  • Compromised lung function: 65% FEV1 % predicted
  • Diagnosed with adult-onset asthma at age 28
  • Lack of asthma control
  • Triple therapy: High-dose ICS/LABA + LAMA
  • 2 severe exacerbations in the past year
  • Compromised lung function: 58% FEV1 % predicted
  • Diagnosed with adult-onset asthma at age 23
  • Lack of asthma control
  • Multiple courses of OCS treatment over
    6 months, potentially leading to6:
    • Symptoms of anxiety and depression
    • Weight gain
    • Type 2 diabetes
    • Vision problems
  • Triple therapy: High-dose ICS/LABA + LTRA


Patient profiles are representative and are not actual DUPIXENT patients.

Examples of patients with an eosinophilic phenotype or with OCS-dependent asthma.

FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.

 

NO BIOMARKER TESTING REQUIRED
for DUPIXENT

for 99% of OCS-dependent asthma patients who are commercially insured4